Is Novartis a Buy After Q2 Numbers?

Filed under: Earnings Reports, Pfizer (PFE), Novartis AG ADS (NVS), Merck and Co (MRK)

I'm looking at Novartis (NVS) late in the trading day. There's less than an hour to go before the market closes. The stock is up 0.4% to $50.97. Is it me, or is Wall Street telling us that it isn't too excited by the drug maker's latest earnings report? Which actually wasn't bad, as far as I can tell. Perhaps the market actually is excited, but the response is being muted by the overall tone of the session (volume is strong, I should mention).



The one-year chart for the equity probably wouldn't make you want to buy this one for a trade. It almost seems as if the chance to get in on a great pullback has come and gone, doesn't it? Well, let's have a peek at the fundamentals.

Continue reading Is Novartis a Buy After Q2 Numbers?

Is Novartis a Buy After Q2 Numbers? originally appeared on BloggingStocks on Thu, 15 Jul 2010 17:30:00 EST. Please see our terms for use of feeds.

Read | Permalink | Email this | Comments
















Novartis - Business - BloggingStocks - Wall Street - Pfizer

Full story at http://www.pheedcontent.com/click.phdo?i=cc50c0e70dd6a4641c178ccb5b1987f7